SIMBRINZA (brinzolamide, brimonidine), glaucoma medicine

No clinical benefit demonstrated in glaucoma by comparison with coadministration of its components individually.

• SIMBRINZA has Marketing Authorisation in decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.
• Brinzolamide (carbonic anhydrase inhibitor) and brimonidine (alpha-2 adrenergic agonist) are second-line treatments. This medicinal product must therefore be reserved for patients with insufficient reduction of IOP with brinzolamide or brimonidine monotherapy.
• It may be used as a substitution for the coadministration of brinzolamide and brimonidine.